Its Japanese partner, Ono Pharmaceutical, is now selling the drug in four doses for adults with partial-onset seizures. The launch follows regulatory approval in Japan in September. Approved in about 50 countries and regions, cenobamate is marketed directly by SK Biopharmaceuticals in the U.S. and through local partners in other major markets. Japan is the world's second-largest epilepsy market after the U.S., with about one million patients.
Tags: SK Biopharmaceuticals, Ono Pharmaceutical, cenobamate, epilepsy drug
Copyright ⓒ Aju Press All rights reserved.